Paclitaxel-induced Peripheral Neuropathy in Patients Receiving Adjuvant Chemotherapy for Breast Cancer

Overview

Journal Int J Clin Oncol

Specialty Oncology

Date 2011 Nov 23

PMID 22105895

Citations 47

Authors

Yuko Tanabe

Kenji Hashimoto

Chikako Shimizu

Akihiro Hirakawa

Kenichi Harano

Mayu Yunokawa

Kan Yonemori

Noriyuki Katsumata

Kenji Tamura

Masashi Ando

Takayuki Kinoshita

Yasuhiro Fujiwara

Affiliations

Soon will be listed here.

Abstract

Background: The long-term outcomes and risk factors of paclitaxel-induced peripheral neuropathy (PIPN) have not yet been fully elucidated.

Methods: We identified 219 breast cancer patients who received paclitaxel as adjuvant chemotherapy between 2002 and 2009. We retrospectively analyzed the incidence, time to onset, duration, and risk factors for PIPN by chart review.

Results: Of the 219 patients, 212 developed PIPN (97%) during a median follow-up time of 57 months (range 5.3-95.5). Median time to PIPN onset was 21 days (range 11-101) for the entire patient population: 35 days (range 14-77) for weekly administration and 21 days (range 11-101) for tri-weekly administration. PIPN caused termination of paclitaxel treatment in 7 patients (4%). Median duration of PIPN was 727 days (range 14-2621 days). PIPN persisted in 64 and 41% of patients at 1 and 3 years after initiating paclitaxel, respectively. Age ≥60 years and severity of PIPN were significantly associated with PIPN duration.

Conclusions: PIPN persists longer in older patients and in those who experience severe neuropathy. Further studies to identify the risk factors for PIPN are warranted.

Citing Articles

A novel model of paclitaxel-induced peripheral neuropathy produces a clinically relevant phenotype in mice.

Osborn L, Bishop M, Rodriguez K, Redling D, Duplechain E, Stephens K bioRxiv. 2025; .

PMID: 39990336 PMC: 11844414. DOI: 10.1101/2025.02.10.637458.

Characterisation of the effects of the chemotherapeutic agent paclitaxel on neuropathic pain-related behaviour, anxiodepressive behaviour, cognition, and the endocannabinoid system in male and female rats.

Di Marino C, Llorente-Berzal A, Diego A, Bella A, Boullon L, Berrocoso E Front Pharmacol. 2025; 15():1505980.

PMID: 39830350 PMC: 11739114. DOI: 10.3389/fphar.2024.1505980.

Kruse F, Bille M, Lendorf M, Vaabengaard S, Birk S Acta Oncol. 2025; 64():78-86.

PMID: 39815403 PMC: 11748177. DOI: 10.2340/1651-226X.2025.42109.

Automated System to Capture Patient Symptoms From Multitype Japanese Clinical Texts: Retrospective Study.

Nishiyama T, Yamaguchi A, Han P, Pereira L, Otsuki Y, Andrade G JMIR Med Inform. 2024; 12:e58977.

PMID: 39316418 PMC: 11462096. DOI: 10.2196/58977.

High prevalence of severe pain is associated with low opioid availability in patients with advanced cancer: Combined database study and nationwide questionnaire survey in Japan.

Hasegawa-Moriyama M, Morioka Y, Hiroi S, Naya N, Suzuki Y, Koretaka Y Neuropsychopharmacol Rep. 2024; 44(3):502-511.

PMID: 38735866 PMC: 11544452. DOI: 10.1002/npr2.12448.

References

Chaudhry V, Rowinsky E, Sartorius S, Donehower R, Cornblath D . Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol. 1994; 35(3):304-11. DOI: 10.1002/ana.410350310. View

Henderson I, Berry D, Demetri G, Cirrincione C, Goldstein L, Martino S . Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003; 21(6):976-83. DOI: 10.1200/JCO.2003.02.063. View

Aplenc R, Glatfelter W, Han P, Rappaport E, La M, Cnaan A . CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemia. Br J Haematol. 2003; 122(2):240-4. DOI: 10.1046/j.1365-2141.2003.04430.x. View

Jones S, Erban J, Overmoyer B, Budd G, Hutchins L, Lower E . Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol. 2005; 23(24):5542-51. DOI: 10.1200/JCO.2005.02.027. View

Rowinsky E, Eisenhauer E, Chaudhry V, Arbuck S, Donehower R . Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol. 1993; 20(4 Suppl 3):1-15. View

Goldhirsch A, Wood W, Gelber R, Coates A, Thurlimann B, Senn H . Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007; 18(7):1133-44. DOI: 10.1093/annonc/mdm271. View

Postma T, Heimans J, Muller M, Ossenkoppele G, Vermorken J, Aaronson N . Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol. 1998; 9(7):739-44. DOI: 10.1023/a:1008344507482. View

Gogas H, Shapiro F, Aghajanian C, Fennelly D, Almadrones L, Hoskins W . The impact of diabetes mellitus on the toxicity of therapy for advanced ovarian cancer. Gynecol Oncol. 1996; 61(1):22-6. DOI: 10.1006/gyno.1996.0090. View

De Laurentiis M, Cancello G, DAgostino D, Giuliano M, Giordano A, Montagna E . Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol. 2008; 26(1):44-53. DOI: 10.1200/JCO.2007.11.3787. View

10.

Rowinsky E, Donehower R . Paclitaxel (taxol). N Engl J Med. 1995; 332(15):1004-14. DOI: 10.1056/NEJM199504133321507. View

11.

Argyriou A, Koltzenburg M, Polychronopoulos P, Papapetropoulos S, Kalofonos H . Peripheral nerve damage associated with administration of taxanes in patients with cancer. Crit Rev Oncol Hematol. 2008; 66(3):218-28. DOI: 10.1016/j.critrevonc.2008.01.008. View

12.

Mamounas E, Bryant J, Lembersky B, Fehrenbacher L, Sedlacek S, Fisher B . Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol. 2005; 23(16):3686-96. DOI: 10.1200/JCO.2005.10.517. View

13.

Seidman A, Berry D, Cirrincione C, Harris L, Muss H, Marcom P . Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer.... J Clin Oncol. 2008; 26(10):1642-9. DOI: 10.1200/JCO.2007.11.6699. View

14.

Trotti A, Colevas A, Setser A, Rusch V, Jaques D, Budach V . CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003; 13(3):176-81. DOI: 10.1016/S1053-4296(03)00031-6. View

15.

Gauchan P, Andoh T, Ikeda K, Fujita M, Sasaki A, Kato A . Mechanical allodynia induced by paclitaxel, oxaliplatin and vincristine: different effectiveness of gabapentin and different expression of voltage-dependent calcium channel alpha(2)delta-1 subunit. Biol Pharm Bull. 2009; 32(4):732-4. DOI: 10.1248/bpb.32.732. View

16.

Nabholtz J, Gelmon K, Bontenbal M, Spielmann M, Catimel G, Conte P . Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol. 1996; 14(6):1858-67. DOI: 10.1200/JCO.1996.14.6.1858. View

17.

Sparano J, Wang M, Martino S, Jones V, Perez E, Saphner T . Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008; 358(16):1663-71. PMC: 2743943. DOI: 10.1056/NEJMoa0707056. View

18.

Siau C, Bennett G . Dysregulation of cellular calcium homeostasis in chemotherapy-evoked painful peripheral neuropathy. Anesth Analg. 2006; 102(5):1485-90. PMC: 1805480. DOI: 10.1213/01.ane.0000204318.35194.ed. View

19.

Buzdar A, Singletary S, Valero V, Booser D, Ibrahim N, Rahman Z . Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res. 2002; 8(5):1073-9. View

20.

Goldhirsch A, Ingle J, Gelber R, Coates A, Thurlimann B, Senn H . Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009; 20(8):1319-29. PMC: 2720818. DOI: 10.1093/annonc/mdp322. View